Ariad Pharmaceuticals Stock Rating Lowered by Summer Street (ARIA)
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded by stock analysts at Summer Street from a “buy” rating to a “neutral” rating in a report issued on Thursday, TheFlyOnTheWall.com reports.
Several other analysts have also recently commented on the stock. Analysts at Chardan Capital downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. Separately, analysts at Oppenheimer cut their price target on shares of Ariad Pharmaceuticals from $24.00 to $7.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $18.75.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 5.83 on Thursday. Ariad Pharmaceuticals has a one year low of $4.00 and a one year high of $25.40. The stock’s 50-day moving average is $19.16 and its 200-day moving average is $18.46. The company’s market cap is $1.079 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 4302.5% on a year-over-year basis. On average, analysts predict that Ariad Pharmaceuticals will post $-1.63 earnings per share for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.